/Edwards%20Lifesciences%20Corp%20phone%20and%20logo%20-by%20T_Schneider%20via%20Shutterstock.jpg)
Based in Irvine, California, Edwards Lifesciences Corporation (EW) is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. With a market cap of $55.34 billion, Edwards Lifesciences is renowned for its cutting-edge technologies, including heart valve therapies and hemodynamic monitoring systems, designed to enhance patient outcomes. The company operates worldwide, emphasizing innovation, quality, and patient care. EW is set to announce its fiscal Q2 earnings results after the market closes on Wednesday, Jul. 24.
Ahead of the event, analysts expect EW to report a profit of $0.70 per share, up 6.1% from $0.66 per share in the year-ago quarter. The company has consistently beaten or matched Wall Street’s EPS estimates in its last four quarterly reports.